Treatment of disorders secondary to organic impairments

Abstract

A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an effective dose of a dopamine, serotonin, and norepinephrine reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

What is claimed:  
     
         1 . A method for enhancing or stimulating neurogenesis comprising administering to a human in need of such treatment a pharmaceutically effective amount of a compound which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine.  
     
     
         2 . The method of  claim 1  wherein the neurogenesis is in the limbic system or paralimbic system.  
     
     
         3 . The method of  claim 1  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         4 . The method of  claim 1  wherein the pharmaceutically effective amount comprises from about 0.25 mg to about 45 mg per day.  
     
     
         5 . A method for treatment of symptoms of Cerebral Palsy comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         6 . The method of  claim 5  wherein the symptoms include spasticity.  
     
     
         7 . The method of  claim 5  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         8 . A method for treatment of  claim 5  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         9 . A method for treatment of  claim 5  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         10 . A method for treatment of symptoms of Torticollis comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         11 . The method of  claim 10  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         12 . A method for treatment of  claim 10  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         13 . A method for treatment of  claim 10  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         14 . A method for treatment of symptoms of Dystonia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         15 . The method of  claim 14  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         16 . A method for treatment of  claim 14  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         17 . A method for treatment of  claim 14  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         18 . A method for treatment of symptoms of Dyskinesia, Tardive Dyskinesia, Lingual Dyskinesia and Facial Dyskinesia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         19 . The method of  claim 18  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         20 . A method for treatment of  claim 18  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         21 . A method for treatment of  claim 18  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         22 . A method for treatment of symptoms of Institutionalization Syndrome and Concentration Camp Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         23 . The method of  claim 22  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         24 . A method for treatment of  claim 22  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         25 . A method for treatment of  claim 22  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         26 . A method for treatment of symptoms of Dementia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         27 . The method of  claim 26  wherein the Dementia is Alzheimer's dementia or non-Alzheimer's dementia.  
     
     
         28 . The method of  claim 26  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         29 . A method for treatment of  claim 26  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         30 . A method for treatment of  claim 26  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.